Frank Verwiel

Frank A. G.
M.
Verwiel currently works at Intellia Therapeutics, Inc., as Chairman from 2020, Bavarian Nordic A, as Independent Director from 2016, Bavarian Nordic GmbH, as Independent Director from 2016, Capsida Biotherapeutics, Inc., as Director from 2019, and Aptalis Pharma US, Inc., as President.
Dr. Verwiel also formerly worked at Aptalis Pharma LLC, as President, Chief Executive Officer & Director from 2011 to 2014, TA SASU, as President & Chief Executive Officer, Aptalis Holdings, Inc., as President, Chief Executive Officer & Director from 2008 to 2014, ObsEva SA, as Chairman from 2016 to 2022, InterMune, Inc., as Independent Director from 2013 to 2014, Achillion Pharmaceuticals, Inc., as Independent Director from 2015 to 2020, Biotechnology Innovation Organization, as Director & Director-Health Section Governing Board from 2013 to 2014, Novartis Gene Therapies, Inc., as Independent Director from 2015 to 2018, and Merck & Co., Inc., as VP-Hypertension & Worldwide Human Health Marketing from 2001 to 2005.
Dr. Verwiel received his Masters Business Admin degree from INSEAD and doctorate degree from Erasmus University Rotterdam.